Molecular testing and next generation sequencing (NGS) for oncogene‐driven mutations, including epidermal growth factor receptor (EGFR) gene mutations, are now the standard of care for the diagnosis and management of metastatic NSCLC [5, 6]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.